Exenatide & Liraglutide ABCD Autumn Meeting, London, March 7 2014 - Slides
ABCD nationwide audits of new diabetes therapies
Dr Bob Ryder1
1City Hospital, Birmingham, UK
Dr Bob Ryder1
1City Hospital, Birmingham, UK
“The NHS is open” - Diabetes UK urges parents to be
4Ts aware during lockdown
The guidance in this document is based on experience from UK centres with the greatest experience of looking after patients with COVID-19 disease and will be updated as more evidence becomes available. The document provides helpful algorithms for management and treatment.
Caution - COVID-19 infection in people with or without previously recognised diabetes increases the risk of the EMERGENCY states of hyperglycaemia with ketones, Diabetic KetoAcidosis (DKA) and Hyperosmolar Hyperglycaemic State (HHS)
Piya Sen Gupta1, Ken Y Thong2, Christopher Walton3, Robert EJ Ryder1, on behalf of ABCD liraglutide audit contributors
1City Hospital, Birmingham, UK
2Rockingham General Hospital, Perth, Australia
3Hull Royal Infirmary, Hull, UK
KY Thong1, P Sen Gupta2, ML Cull2, KA Adamson3, DS Dove4, SV Rowles5, S Tarpey5, C Duncan6 , J Chalmers6, R Harper7, P McDonald7, U Brennan7, C Walton8, REJ Ryder2 on behalf of the ABCD Nationwide exenatide* and liraglutide† audit contributors
KY Thong1, P Sen Gupta1,2, REJ Ryder1
1Department of Diabetes, City Hospital, Birmingham, UK
2Diabetes Research Group, King’s College, London, UK
Sen Gupta P1, Thong KY1, Armstrong M2, Newsome PN2, Winocour P3, Ryder REJ1
1City Hospital, Birmingham, UK
2University of Birmingham, Birmingham, UK
3Queen Elizabeth Hospital, Welwyn Garden City, UK
Ryder REJ1, Thong KY2, Blann A1, Phillips S3, Barwell N4, Kelly C4, Semple C5, Struthers S5, Sen Gupta P1, on behalf of the ABCD Nationwide Liraglutide Audit contributors
1City Hospital, Birmingham, UK
2Rockingham General Hospital, Perth, Australia
3Gloucestershire Royal Hospital, UK